Eli Lilly's Mounjaro Won't Have Separate Sleep Apnea Label in EU.

The European Medicines Agency has decided not to reclassify Eli Lilly & Co.'s drug Mounjaro as a treatment for sleep apnea, stating that its approval as a weight-loss medicine already covers its use. Data on Mounjaro's effects on sleep apnea can be included in its product information for doctors' awareness. Eli Lilly and Novo Nordisk A/S are competing in the obesity drug market, with Mounjaro showing potential for treating various conditions beyond obesity. [Extracted from the article]